ClinicalTrials.gov record
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
ClinicalTrials.gov ID: NCT00355082
Public ClinicalTrials.gov record NCT00355082. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures
Study identification
- NCT ID
- NCT00355082
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 226 participants
Conditions and interventions
Conditions
Interventions
- lamotrigine, 300 mg/day Drug
- lamotrigine, 250 mg/day Drug
Drug
Eligibility (public fields only)
- Age range
- 13 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Oct 31, 2008
- Completion
- Oct 31, 2008
- Last update posted
- Jan 1, 2017
2006 – 2008
United States locations
- U.S. sites
- 67
- U.S. states
- 31
- U.S. cities
- 59
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Alabaster | Alabama | 35007 | — |
| GSK Investigational Site | Litchfield Park | Arizona | 85340 | — |
| GSK Investigational Site | Mesa | Arizona | 85201 | — |
| GSK Investigational Site | Phoenix | Arizona | 85003 | — |
| GSK Investigational Site | Phoenix | Arizona | 85013 | — |
| GSK Investigational Site | Tucson | Arizona | 85724 | — |
| GSK Investigational Site | Tucson | Arizona | 85741 | — |
| GSK Investigational Site | Fayetteville | Arkansas | 72703 | — |
| GSK Investigational Site | Los Angeles | California | 90073 | — |
| GSK Investigational Site | Pasadena | California | 91105 | — |
| GSK Investigational Site | Santa Ana | California | 92705 | — |
| GSK Investigational Site | Santa Monica | California | 90404 | — |
| GSK Investigational Site | Danbury | Connecticut | 06810 | — |
| GSK Investigational Site | Fairfield | Connecticut | 06824 | — |
| GSK Investigational Site | Newark | Delaware | 19713 | — |
| GSK Investigational Site | Jacksonville | Florida | 32224 | — |
| GSK Investigational Site | Loxahatchee Groves | Florida | 33470 | — |
| GSK Investigational Site | Sunrise | Florida | 33351 | — |
| GSK Investigational Site | Tampa | Florida | 33613 | — |
| GSK Investigational Site | Atlanta | Georgia | 30338 | — |
| GSK Investigational Site | Atlanta | Georgia | 30342 | — |
| GSK Investigational Site | Decatur | Georgia | 30033 | — |
| GSK Investigational Site | Boise | Idaho | 83702 | — |
| GSK Investigational Site | Chicago | Illinois | 60611 | — |
| GSK Investigational Site | Chicago | Illinois | 60637 | — |
| GSK Investigational Site | Flossmoor | Illinois | 60422 | — |
| GSK Investigational Site | Urbana | Illinois | 61801 | — |
| GSK Investigational Site | Des Moines | Iowa | 50309 | — |
| GSK Investigational Site | Lexington | Kentucky | 40513 | — |
| GSK Investigational Site | Lexington | Kentucky | 40536 | — |
| GSK Investigational Site | Louisville | Kentucky | 40202 | — |
| GSK Investigational Site | New Orleans | Louisiana | 70115 | — |
| GSK Investigational Site | Bethesda | Maryland | 20817 | — |
| GSK Investigational Site | Glen Burnie | Maryland | 21061 | — |
| GSK Investigational Site | Pikesville | Maryland | 21208 | — |
| GSK Investigational Site | Springfield | Massachusetts | 01104 | — |
| GSK Investigational Site | Detroit | Michigan | 48202 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55455 | — |
| GSK Investigational Site | Saint Cloud | Minnesota | 56303 | — |
| GSK Investigational Site | Hattiesburg | Mississippi | 39401 | — |
| GSK Investigational Site | Kansas City | Missouri | 64111 | — |
| GSK Investigational Site | St Louis | Missouri | 63104 | — |
| GSK Investigational Site | St Louis | Missouri | 63110 | — |
| GSK Investigational Site | Henderson | Nevada | 89014 | — |
| GSK Investigational Site | Las Vegas | Nevada | 81902 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89106 | — |
| GSK Investigational Site | Edison | New Jersey | 08818 | — |
| GSK Investigational Site | Vorhees | New Jersey | 08043 | — |
| GSK Investigational Site | Lawrence | New York | 11559 | — |
| GSK Investigational Site | Plainview | New York | 11803 | — |
| GSK Investigational Site | Syracuse | New York | 13210 | — |
| GSK Investigational Site | Asheville | North Carolina | 28803 | — |
| GSK Investigational Site | Columbus | Ohio | 43210-1296 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| GSK Investigational Site | Sellersville | Pennsylvania | 18960 | — |
| GSK Investigational Site | Dallas | Texas | 75230 | — |
| GSK Investigational Site | Houston | Texas | 77025 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | San Antonio | Texas | 78258 | — |
| GSK Investigational Site | Temple | Texas | 76502 | — |
| GSK Investigational Site | Midvale | Utah | 84047 | — |
| GSK Investigational Site | Renton | Washington | 98055 | — |
| GSK Investigational Site | Charleston | West Virginia | 25301 | — |
| GSK Investigational Site | Morgantown | West Virginia | 26506 | — |
| GSK Investigational Site | Madison | Wisconsin | 53715 | — |
| GSK Investigational Site | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00355082, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 1, 2017 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00355082 live on ClinicalTrials.gov.